N1-(4-氰基-2-乙基苯基)乙酰胺 | 34921-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N1-(4-氰基-2-乙基苯基)乙酰胺
• 英文名称: N-(4-cyano-2-ethyl-phenyl)-acetamide
• 英文别名: N-(4-cyano-2-ethylphenyl)acetamide；4-cyano-2-ethylacetanilide；4-Acetamido-3-ethylbenzonitril；4-Cyano-2-aethylacetanilid
• CAS: 34921-76-1
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD00221461
• 分子量: 188.229
• InChiKey: SQBQTZGZKSMASP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

SDS

Name:	N1-(4-Cyano-2-ethylphenyl)acetamide 97% Material Safety Data Sheet
Synonym:	4-Cyano-2-ethylacetanilid
CAS:	34921-76-1

Section 1 - Chemical Product MSDS Name:N1-(4-Cyano-2-ethylphenyl)acetamide 97% Material Safety Data Sheet
Synonym:4-Cyano-2-ethylacetanilid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
34921-76-1	N1-(4-Cyano-2-ethylphenyl)acetamide	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 34921-76-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 178 - 180 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12N2O
Molecular Weight: 188

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 34921-76-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(4-Cyano-2-ethylphenyl)acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 34921-76-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 34921-76-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 34921-76-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N1-(4-氰基-2-乙基苯基)乙酰胺 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 22.0h， 以84.5%的产率得到4-氨基-3-乙基苯甲酸
  参考文献：
  名称：

  PRODRUGS OF OPIOIDS AND USES THEREOF

  摘要：

  本发明涉及阿片类镇痛药的前药以及含有此类前药的药物组合物。本发明提供了通过前述前药增加阿片类镇痛药的生物利用度，从而提供更一致的疼痛缓解方法。该发明还提供了减少阿片类镇痛药对胃肠道的副作用的方法。

  公开号：

  US20110190267A1
• 作为产物：
  描述：

  2-乙基苯胺 在 bis(dibenzylideneacetone)-palladium⁽⁰⁾ sodium hydroxide 、 溴 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N1-(4-氰基-2-乙基苯基)乙酰胺
  参考文献：
  名称：

  Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators

  摘要：

  Pharmacokinctic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.076

文献信息

• [EN] TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION<br/>[FR] TRIFLUOROMÉTHOXYLATION D'ARÈNES VIA UNE MIGRATION INTRAMOLÉCULAIRE DU GROUPE TRIFLUOROMÉTHOXY
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2016057931A1

  公开（公告）日：2016-04-14

  The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: (I), wherein A is an aryl or heteroaryl, each with or without subsutitution; and R1 is -H, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), - (alkylaryl), - (alkylheteroaryl), -NH-(alkyl), -N(alkyl)2, -NH-(alkenyl), -NH-(alkynyl) -NH-(aryl), -NH-(heteroaryl), -O-(alkyl), -O-(alkenyl), -O-(alkynyl), -O-(aryl), -O-(heteroaryl), -S-(alkyl), -S- (alkenyl), -S-(alkynyl), -S-(aryl), or -S-(heteroaryl), comprising: (a) reacting a compound having the structure: (II), with a trifluoromethylating agent in the presence of a base in a first suitable solvent under conditions to produce a compound having the structure: (III); and (b) maintaining the compound produced in step (a) in a second suitable solvent under conditions sufficient to produce the trifluoromethoxylated aryl or trifluormethoxylated heteroaryl having the structure: (I).

  本发明提供了一种生产具有结构式(I)的三氟甲氧基取代的芳基或三氟甲氧基取代的杂芳基的方法，其中A是芳基或杂芳基，每个芳基或杂芳基可以有或无取代基；R1是-H，-(烷基)，-(烯基)，-(炔基)，-(芳基)，-(杂芳基)，-(烷基芳基)，-(烷基杂芳基)，-NH-(烷基)，-N(烷基)2，-NH-(烯基)，-NH-(炔基)-NH-(芳基)，-NH-(杂芳基)，-O-(烷基)，-O-(烯基)，-O-(炔基)，-O-(芳基)，-O-(杂芳基)，-S-(烷基)，-S-(烯基)，-S-(炔基)，-S-(芳基)或-S-(杂芳基)，包括：(a)使具有结构式(II)的化合物与三氟甲基化剂在第一适宜溶剂中的碱的存在下反应，在适宜条件下生成具有结构式(III)的化合物；以及(b)将步骤(a)中产生的化合物维持在第二适宜溶剂中，在足以生成具有结构式(I)的三氟甲氧基取代的芳基或三氟甲氧基取代的杂芳基的条件下保持。
• AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
  申请人：Bolli Martin

  公开号：US20100087417A1

  公开（公告）日：2010-04-08

  The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  该发明涉及新型氨基吡啶衍生物，其制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫调节剂。
• [EN] PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DU FACTEUR D'ACTIVATION PLAQUETTAIRE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011005608A1

  公开（公告）日：2011-01-13

  Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

  环己基磺胺化合物是血小板活化因子（PAF）受体拮抗剂。这些化合物可能对治疗动脉粥样硬化或其他PAF介导的疾病有用，包括炎症性、心血管和免疫性疾病。
• PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS
  申请人：Ogawa Anthony

  公开号：US20120108595A1

  公开（公告）日：2012-05-03

  Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

  环己基磺酰胺化合物是血小板活化因子(PAF)受体拮抗剂。该化合物可能有用，例如，用于治疗动脉粥样硬化或其他PAF介导的疾病，包括炎症，心血管和免疫疾病。
• Platelet-activating factor receptor antagonists
  申请人：Ogawa Anthony

  公开号：US09029377B2

  公开（公告）日：2015-05-12

  Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

  环己基磺酰胺化合物，可作为血小板活化因子（PAF）受体拮抗剂。这些化合物可能有用，例如用于治疗动脉粥样硬化或其他PAF介导的疾病，包括炎症性、心血管和免疫性疾病。